-
Product Insights
NewNet Present Value Model: Immunocore Holdings Plc’s IMCF-106C
Empower your strategies with our Net Present Value Model: Immunocore Holdings Plc's IMCF-106C report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s PF-07038124
Empower your strategies with our Net Present Value Model: Pfizer Inc's PF-07038124 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebentafusp in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebentafusp in Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebentafusp in Uveal Melanoma Drug Details: Tebentafusp-Tebn (Kimmtrak) is a bispecific gp100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Ovarian Cancer Drug Details: IMCF-106C is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Small-Cell Lung Cancer Drug Details: IMCF-106C is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Endometrial Cancer Drug Details: IMCF-106C is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Fallopian Tube Cancer Drug Details: IMCF-106C is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Peritoneal Cancer Drug Details: IMCF-106C is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMCF-106C in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCF-106C in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCF-106C in Head And Neck Squamous...